Filing Flows › AtriCure (ATRC) › Q3 2026 › vs Q3 2025
AtriCure (ATRC) Q3 2026 vs Q3 2025 (year over year)
AtriCure's revenue rose $20.2M (+15%) from $134M in Q3 2025 to $154M in Q3 2026. Gross margin 77.3% against 75.5% (+1.8 pts).
AtriCure, Q3 2026: revenue $154M (+15% year over year), operating margin 2.8%, net earnings $4.1M, operating cash flow $30.3M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Gross margin | 77.3% | 75.5% | +1.8 pts |
| Operating margin | 2.8% | 0.2% | +2.7 pts |
| Net margin | 2.6% | -0.2% | +2.8 pts |
| Free cash flow margin | 15.5% | 18.0% | -2.5 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $154M | $134M | $20.2M | +15% |
| Gross profit | $119M | $101M | $18.0M | +18% |
| Cost of revenue | $35.1M | $32.9M | $2.2M | +7% |
| Operating profit | $4.4M | $208K | $4.1M | 21× |
| Operating expenses | $115M | $101M | $13.9M | +14% |
| Pre-tax earnings | $4.0M | −$86K | $4.1M | — |
| Research & development | $32.1M | $22.9M | $9.2M | +40% |
| SG&A | $82.9M | $78.2M | $4.6M | +6% |
| Income tax benefit | $47K | −$181K | $228K | — |
| Net earnings | $4.1M | −$267K | $4.3M | — |
| Depreciation & amortization | $5.5M | $5.2M | $306K | +6% |
| Share-based compensation | $12.5M | $12.4M | $54K | +0.4% |
| Working capital & other | $8.3M | $9.4M | −$1.1M | -12% |
| Operating cash flow | $30.3M | $26.7M | $3.6M | +13% |
| Free cash flow (OCF − capex) | $23.9M | $24.1M | −$177K | -0.7% |
| Capital expenditures | $6.4M | $2.6M | $3.8M | +145% |
Questions
How much did AtriCure's revenue grow year over year in Q3 2026?
AtriCure's revenue rose $20.2M (+15%) from $134M in Q3 2025 to $154M in Q3 2026. Gross margin 77.3% against 75.5% (+1.8 pts).